Verastem's VS-7375 gets FDA fast track for lung cancer

Key facts

• FDA granted Fast Track designation to Verastem's VS-7375.
• The designation is for treating KRAS-mutated non-small cell lung cancer.

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Verastem's investigational drug VS-7375. This designation is for the treatment of patients with KRAS-mutated non-small cell lung cancer. Fast Track designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.